Osteomyelitis—infection of the bone—is one of the most consequential complications of the diabetic foot. It underlies a large share of non-healing plantar ulcers and is a frequent step on the pathway to amputation. Yet many of the questions clinicians face during treatment, such as whether to operate, which antibiotic to choose, and how long to continue it, have historically been answered more by tradition than by evidence. Over the past decade, randomized trials and updated international guidelines have begun to reshape that picture, generally in the direction of less surgery and shorter courses of antibiotics than were once routine. This article summarizes what current peer-reviewed evidence says about managing diabetic foot osteomyelitis (DFO).
Confirming the Diagnosis Before Committing to Treatment
Because treatment is prolonged and carries real risks, accurate diagnosis matters. The 2023 IWGDF/IDSA guidelines recommend an initial combination of the probe-to-bone test, plain radiographs, and inflammatory markers (ESR, CRP, or procalcitonin) to establish or exclude bone infection, reserving MRI for cases that remain in doubt after these first-line studies. MRI carries high sensitivity and specificity—roughly 90% and 83%, respectively—and helps distinguish osteomyelitis from Charcot changes. When bone infection is confirmed and antibiotics are planned, obtaining a bone specimen for culture, rather than a superficial swab, allows targeted therapy and reduces unnecessary broad-spectrum exposure.
Surgery or Antibiotics First?
A central shift in modern management is the recognition that not every case of DFO requires surgery. The 2023 IWGDF/IDSA guidelines note that primarily medical (antibiotic) management is a reasonable option for selected patients—typically those with forefoot osteomyelitis, without significant peripheral arterial disease, and without extensively exposed or necrotic bone. Randomized data support this: in a comparative trial of antibiotics versus conservative surgery, healing rates were similar between the two approaches, indicating that a carefully chosen medical strategy can spare some patients an operation without compromising outcomes.
This does not make surgery obsolete. Debridement or limited resection remains important when there is spreading soft-tissue infection, an abscess, extensive bone destruction, mechanical instability, or failure of medical therapy. The practical message from the evidence is one of individualization: the decision should weigh the location and extent of infection, the patient’s vascular status, and the condition of the surrounding soft tissue.
How Long Should Antibiotics Continue?
The duration of antibiotic therapy has been one of the most actively studied questions in the field, and the trend is toward shorter courses. In a multicenter randomized study, six weeks of antibiotics produced remission rates comparable to twelve weeks in nonsurgically treated DFO, without the added toxicity that longer exposure brings. On that basis, roughly six weeks became a widely accepted benchmark for medically managed bone infection.
More recent work has tested whether even shorter courses suffice, particularly after surgical debridement. A prospective randomized pilot trial comparing three versus six weeks of post-debridement antibiotics found the shorter course to be non-inferior for clinical remission, though the authors appropriately cautioned that the study was small and used a wide non-inferiority margin. A 2025 systematic review and meta-analysis synthesizing this literature similarly concluded that shorter durations often achieve outcomes comparable to longer ones in appropriately selected patients, while reducing the burden of prolonged treatment.
Why Shorter Can Be Better
The appeal of shorter therapy is not merely convenience. Extended antibiotic courses carry risks of adverse drug reactions, Clostridioides difficile infection, and the selection of resistant organisms, all of which matter in a population already prone to repeated infections. When the infected bone has been surgically removed, the remaining rationale for prolonged treatment is weaker, which is why post-surgical regimens can often be condensed. Conversely, when bone is retained and treated medically, a longer course remains standard.
Key Takeaways
Current evidence supports a measured, individualized approach to diabetic foot osteomyelitis. Diagnosis rests on a stepwise combination of clinical testing, imaging, and, when needed, bone culture. Medical management is a legitimate first option for selected forefoot infections without critical ischemia, while surgery retains a defined role for extensive, unstable, or refractory disease. Antibiotic duration is trending shorter—around six weeks for medically treated bone and potentially as little as three weeks after adequate surgical debridement—with the goal of achieving remission while minimizing the harms of overtreatment. As with most aspects of diabetic foot care, outcomes depend on matching the intensity of treatment to the specific clinical situation rather than applying a single fixed protocol.
References
Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clinical Infectious Diseases. 2023 (also published in Diabetes/Metabolism Research and Reviews, 2024).
Tone A, Nguyen S, Devemy F, et al. Six-week versus twelve-week antibiotic therapy for nonsurgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. Diabetes Care. 2015;38(2):302–307.
Gariani K, Pham TT, Kressmann B, et al. Three weeks versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: a prospective, randomized, noninferiority pilot trial. Clinical Infectious Diseases. 2021;73(7):e1539–e1545.
Impact of antibiotic duration in the management of diabetic foot osteomyelitis: a systematic review and meta-analysis. Clinical Microbiology and Infection Communications. 2025.
State-of-the-art update for diagnosing diabetic foot osteomyelitis: a narrative review. Journal of Yeungnam Medical Science. 2023.
Comments
